University of Canberra

Epiaxis Therapeutics Pty Ltd.

Sudha Rao

Anjum Zafar

Anjurn Zafar

Peter Milburn

Disclosed are methods and agents for predicting responses to therapy. More particularly, the present disclosure relates to methods and agents for detecting different forms of Programmed Death Ligand-1 (PD-L1) in cancer cells, which are useful for detecting location of PD-L1 in a cellular compartment (e.g., nucleus, cytoplasm, cell membrane) of a cancer cell, for predicting the likelihood of response of a cancer cell to therapy including immunotherapy, for stratifying a cancer patient as a likely responder or non-responder to a therapy, for managing treatment of a cancer patient, and for predicting clinical outcomes.

Agents and methods for predicting response to therapy

Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-&#x3b8;) for inhibiting the growth of PKC-&#x3b8;-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.

Stem cell modulation II

Disclosed are compositions and methods for modulating cancer stem cells. More particularly, the present invention discloses the use of lysine demethylase (LSD) inhibitors and protein kinase C theta inhibitors (PKC-&#x3b8;) for inhibiting the growth of LSD- and/or PKC-&#x3b8;-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including non-metastatic and metastatic cancer and/or for preventing cancer recurrence.

Compositions for modulating cancer stem cells and uses therefor

Disclosed are proteinaceous molecules and their use in conditions associated with PKC-&#x3b8; overexpression, such as cancer. More particularly, the present invention discloses proteinaceous molecules and their use in altering at least one of (i) formation; (ii) proliferation; (iii) maintenance; (iv) epithelial to mesenchymal cell transition; or (v) mesenchymal to epithelial cell transition of a PKC-&#x3b8; overexpressing cell.

Proteinaceous compounds and uses therefor

Disclosed are compositions and methods that use lysine demethylase inhibitors for inhibiting the growth of cancer stem cells or tumor initiating cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells and/or for preventing cancer recurrence.

Growing community of inventors

McKellar, Australia

Sudha Rao